Last updated: April 24, 2026
Who supplies metolazone API and what is the manufacturing footprint?
Metolazone is supplied through multiple API and finished-dose channels. Demand typically runs through:
- Generic tablets (most market activity)
- Direct API supply to generic manufacturers and formulators
- Contract manufacturing for tablets and packaging
A reliable supplier map depends on whether the focus is API, finished dosage, or both. This answer is constrained to supplier lists where verifiable public sourcing exists.
Top finished-dose and distribution channels (global)
The most visible public supplier set for metolazone is through branded and generic finished-dose labels, which are distributed by large generic and specialty pharmaceutical companies and their partners. Public listings appear in regulatory product databases and market catalogs, where companies are shown as marketing authorizers or distributors rather than API manufacturers.
Examples of commonly listed finished-dose label/distribution entities
| Entity type |
Example entities appearing in public product listings |
Notes |
| Finished-dose marketers/generics |
Major global generic manufacturers (varies by country) |
Often changes by market authorization and label version |
| Local distributors |
Country-specific wholesalers and distributors |
Labels and packagers differ by jurisdiction |
No complete, single global “supplier for metolazone” list is consistent across jurisdictions because product registrations and distributors are country-specific.
What API suppliers exist for metolazone?
Publicly searchable supplier registers for API typically require linkage to:
- DMF (Drug Master File) submissions
- CEP and regulatory filings
- Importer/MAH listings tied to specific packaging and batch releases
A complete API supplier roster cannot be compiled from the information available here without risking inaccuracies (API suppliers change and are often not fully disclosed in public product databases).
What are the most common dosage forms and how does that drive supplier selection?
Metolazone is commercially supplied primarily as:
- Tablets (oral solid dose)
- Strengths commonly seen across markets: 2.5 mg (also seen as 1 mg in some markets)
This matters because tablet manufacturing and packaging are usually where most contract relationships sit, while API sourcing may be upstream and less visible publicly.
Supply chain structure
| Layer |
Typical supplier role |
What is usually visible |
| API |
Raw material manufacturer |
Often visible only via DMF/CEP-linked filings |
| Tablet manufacture |
Contract manufacturer or in-house |
Visible through finished-dose registrations |
| Packaging |
Local packager |
Visible in local regulatory listings |
| Distribution |
MAH or distributor |
Visible through product databases by country |
How to interpret supplier lists for metolazone in regulatory databases
When you see a “supplier” in a drug database entry, it can mean:
- Marketing authorization holder (MAH)
- Importer
- Distributor
- Labeler
- Sometimes the manufacturer of record for the finished product
For metolazone, supplier visibility is strongest at the finished-dose layer, not always at the API layer.
Practical sourcing routes for metolazone
Route A: Source finished-dose tablets
Use national regulatory databases to identify:
- Tablet MAHs
- Manufacturers of record for each marketed strength
- Changes across pack sizes and label versions
Route B: Source metolazone API
Use DMF/CEP-linked information to identify:
- API manufacturer tied to filings
- Alternate API suppliers if multiple approvals exist for the same drug substance
Route C: Use contract manufacturing
If you need tablets and secondary packaging:
- Select contract manufacturers with demonstrated capability for oral solid doses
- Confirm API sourcing through your quality agreement chain
Key Takeaways
- Metolazone supply is most consistently visible through finished-dose tablet marketing/distribution rather than full public disclosure of API manufacturers.
- A single universal “metolazone supplier list” does not hold across countries because product authorizations and distributors vary by jurisdiction.
- For procurement decisions, separate finished-dose suppliers from API suppliers and validate through regulatory product listings (finished dose) and DMF/CEP-linked filings (API).
FAQs
-
What is the most common metolazone dosage form in global markets?
Oral solid tablets.
-
Is metolazone supply handled primarily by API suppliers or tablet manufacturers?
Finished-dose manufacturers and distributors are most visible publicly; API sourcing is typically upstream and tied to DMF/CEP information.
-
Why do metolazone suppliers differ by country?
Because marketing authorizations, importers, packagers, and manufacturers of record are jurisdiction-specific.
-
What should procurement teams confirm when sourcing metolazone tablets?
Manufacturer of record, strength, pack configuration, and regulatory status in the target market.
-
What is the best way to identify metolazone API suppliers?
Trace API manufacturer identity through DMF/CEP-linked regulatory filings rather than finished-dose label entries.
Sources (APA)
[1] U.S. Food and Drug Administration (FDA). Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency (EMA). European public assessment reports and EPAR/EPAR product information. https://www.ema.europa.eu/en
[3] UK Medicines and Healthcare products Regulatory Agency (MHRA). Drug product databases and licensing information. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
